Zimbabwe has rejected a major US healthcare agreement worth 367 million US dollars (£272m) spanning five years over the United States' demand for sensitive biological samples.
This rejection came to light after a government memo dated December was leaked, indicating that President Emmerson Mnangagwa felt the agreement was "unbalanced".
An official representative later explained that the United States was seeking genetic material for scientific study and commercial purposes but refused to guarantee the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had provided over $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged further talks to find a deal acceptable to all parties so the country's critical HIV treatment initiative can be sustained.
Wider Background
This development follows a similar situation in neighbouring Kenya, where a court blocked a similar health funding agreement after concerns were filed about the security of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed aid for the American government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government deals to enhance transparency and accountability.
Based on reports, Sixteen nations in Africa have to date agreed to these new health pacts, representing more than $18.3bn in committed funds.
Details of the Rejected Agreement
The money for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered significant benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently receiving HIV treatment through US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to surrender its genetic material and health information for a long time, with no corresponding promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"Effectively, our country would supply the basic resources for medical research without any certainty that the final treatments would be available to our people should a future disease outbreak emerge."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining frameworks already established via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to deal with future pandemics.
"This mechanism is designed to guarantee that when a nation provides its samples, the resulting advantages – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to further dialogue with our US partners on how future collaboration could be designed in a way that honours the independence and dignity of both nations."
Medical Community Response
A leading public health body said it understood the government's concerns, but urged that talks must proceed given that much of the country's Aids initiatives relied on international support.
"In cases where specific concerns arise, including those relating to data governance or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," it said.
This impasse emphasises the complex challenges between accepting vital international aid and safeguarding a country's data in an increasingly data-driven world.